HALOZYME THERAPEUTICS, INC. (HALO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, HALOZYME THERAPEUTICS, INC. reported revenue of $1.40B, up 37.6% from the prior year. The company was profitable, with a net margin of 22.7%. It held $2.53B in total assets against $2.48B in total liabilities.
Key ratios (FY2025)
33.6%
Operating margin
22.7%
Net margin
649.2%
Return on equity
+37.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M | $195.99M | $151.86M | $316.61M | — |
| Cost of Revenue | $228.77M | $159.42M | $192.36M | $139.30M | $81.41M | $43.37M | $45.55M | $10.14M | $31.15M | — |
| Operating Income | $469.01M | $551.48M | $337.57M | $267.53M | $275.90M | $144.25M | -$67.61M | -$69.33M | $81.00M | -$83.21M |
| Net Income | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M | -$72.24M | -$80.33M | $62.97M | -$103.02M |
| EPS (Diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
| Total Assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.92M | $565.87M | $440.25M | $519.95M | $261.51M |
| Total Liabilities | $2.48B | $1.70B | $1.65B | $1.67B | — | — | — | — | — | — |
| Shareholders' Equity | $48.81M | $363.82M | $83.81M | $169.80M | $196.95M | $151.05M | $91.77M | $248.89M | $208.37M | -$32.48M |
| Cash & Equivalents | $133.82M | $115.85M | $118.37M | $234.19M | $118.72M | $147.70M | $120.18M | $57.94M | $168.74M | $66.76M |
| Operating Cash Flow | $651.56M | $479.06M | $388.57M | $240.11M | $299.44M | $55.45M | -$85.42M | -$49.50M | $134.05M | -$50.38M |
| Capital Expenditures | $6.97M | $10.70M | $15.29M | $4.81M | $1.46M | $2.50M | $4.04M | $4.66M | $1.35M | $3.14M |
| Shares Outstanding | 117.78M | 123.14M | 126.77M | 135.15M | 137.50M | 135.03M | 136.71M | 144.73M | 142.79M | 129.50M |